Ram Mukunda - Mar 21, 2022 Form 4 Insider Report for India Globalization Capital, Inc. (IGC)

Role
CEO, Director
Signature
/s/ Ram Mukunda
Stock symbol
IGC
Transactions as of
Mar 21, 2022
Transactions value $
$0
Form type
4
Date filed
6/28/2022, 07:08 PM
Previous filing
Dec 23, 2021
Next filing
May 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGC Common Stock Options Exercise $0 +333K +15.33% $0.00 2.51M Mar 21, 2022 Direct F1
transaction IGC Common Stock Options Exercise $0 +600K +23.92% $0.00 3.11M May 31, 2022 Direct F2
transaction IGC Common Stock Options Exercise $0 +200K +6.43% $0.00 3.31M Jun 1, 2022 Direct F2
transaction IGC Common Stock Options Exercise $0 +16.7K +2.29% $0.00 744K Mar 21, 2022 BY SPOUSE F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGC Restricted Stock Units Options Exercise $0 -333K -7.94% $0.00 3.87M Mar 21, 2022 Common Stock 333K $0.00 Direct F1
transaction IGC Restricted Stock Units Options Exercise $0 -600K -15.52% $0.00 3.27M May 31, 2022 Common Stock 600K $0.00 Direct F2
transaction IGC Restricted Stock Units Options Exercise $0 -200K -6.12% $0.00 3.07M Jun 1, 2022 Common Stock 200K $0.00 Direct F2
transaction IGC Restricted Stock Units Options Exercise $0 -16.7K -33.33% $0.00 33.3K Mar 21, 2022 Common Stock 16.7K $0.00 BY SPOUSE F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 19, 2021, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2022.
F2 On December 20, 2021, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved. On May 31 and June 1, 2022, two of the milestones related to our IGC-AD1 clinical trials were reached.